Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2015

Open Access 01-12-2015 | Research article

Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis

Authors: Cheryl McQuire, Angela Hassiotis, Bronwyn Harrison, Stephen Pilling

Published in: BMC Psychiatry | Issue 1/2015

Login to get access

Abstract

Background

Psychotropic medications are frequently used to treat challenging behaviour in children with intellectual disabilities, despite a lack of evidence for their efficacy. This systematic review and meta-analysis aimed to determine the safety and efficacy of pharmacological interventions for challenging behaviour among children with intellectual disabilities.

Methods

Electronic databases were searched and supplemented with a hand search of reference lists and trial registries. Randomised controlled trials of pharmacological interventions for challenging behaviour among children with intellectual disabilities were included. Data were analysed using meta-analysis or described narratively if meta-analysis was not possible. For quality assessment, the Cochrane Risk of Bias tool and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach were used.

Results

Fourteen studies including 912 participants met inclusion criteria. Antipsychotic medication reduced challenging behaviour among children with intellectual disabilities in the short-term (SMD = −1.09, p < 0.001 for risperidone; SMD = −0.64, p <0.001 for aripiprazole). However, there were significant side-effects including elevated prolactin levels (SMD = 3.22, p < 0.001) and weight gain (SMD = 0.82, p < 0.001). Evidence was inconclusive regarding the effectiveness of anticonvulsants and antioxidants for reducing challenging behaviour. The quality of all evidence was low and there were no long term follow up studies.

Conclusions

Antipsychotic medications appear to be effective for reducing challenging behaviour in the short-term among children with intellectual disabilities, but they carry a risk of significant side effects. Findings from this review must be interpreted with caution as studies were typically of low quality and most outcomes were based on a small number of studies. Further long-term, high-quality research is needed to determine the effectiveness and safety of psychotropic medication for reducing challenging behaviour.
Appendix
Available only for authorised users
Literature
1.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders 5th ed. Arlington, Va: American Psychiatric Association; 2013.CrossRef
2.
Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011;32:419–36.CrossRefPubMed
3.
White P, Chant D, Edwards N, Townsend C, Waghorn G. Prevalence of intellectual disability and comorbid mental illness in an Australian community sample. Aust NZ J Psychiat. 2005;39:395–400.CrossRef
4.
Emerson E, Baines S, Allerton L, Welch V. Health inequalities and people with learning disabilities in the UK: 2010. Durham: Improving Health & Lives: Learning Disabilities Observatory; 2010.
5.
Emerson E, Stewart L. Challenging Behaviour. 3rd ed. Cambridge: Cambridge University Press; 2011.CrossRef
6.
Jones S, Cooper SA, Smiley E, Allan L, Williamson A, Morrison J. Prevalence of, and factors associated with, problem behaviors in adults with intellectual disabilities. J Nerv Ment Dis. 2008;196:678–86.CrossRefPubMed
7.
Allen DG, Lowe K, Moore K, Brophy S. Predictors, costs and characteristics of out of area placement for people with intellectual disability and challenging behaviour. J Intell Disabil Res. 2007;51:409–16.CrossRef
8.
Myrbakk E, Von Tetzcnner S. The prevalence of behavior problems among people with intellectual disability living in community settings. J Ment Health Res Intell Disabil. 2008;1:205–22.CrossRef
9.
Cooper V. Support and services for individuals with intellectual disabilities whose behaviour is described as challenging, and the impact of recent inquiries. Adv Ment Health Intell Disab. 2012;6:229–35.CrossRef
10.
Devereux JM, Hastings RP, Noone SJ, Firth A, Totsika V. Social support and coping as mediators or moderators of the impact of work stressors on burnout in intellectual disability support staff. Res Dev Disabil. 2009;30:367–77.CrossRefPubMed
11.
Hastings RP, Horne S, Mitchell G. Burnout in direct care staff in intellectual disability services: a factor analytic study of the Maslach Burnout Inventory. J Intell Disabil Res. 2004;48:268–73.CrossRef
12.
Griffiths H, Halder N, Chaudhry N. Antipsychotic prescribing in people with intellectual disabilities: a clinical audit. Adv Ment Health Intell Disabil. 2012;6:215–22.CrossRef
13.
Haw C, Stubbs J. A survey of off-label prescribing for inpatients with mild intellectual disability and mental illness. J Intell Disabil Res. 2005;49:858–64.CrossRef
14.
Paton C, Flynn A, Shingleton-Smith A, McIntyre S, Bhaumik S, Rasmussen J, et al. Nature and quality of antipsychotic prescribing practice in UK psychiatry of intellectual disability services. J Intell Disabil Res. 2011;55:665–74.CrossRef
15.
Tsiouris JA. Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment? J Intell Disab Res. 2010;54:1–16.CrossRef
16.
Gazizova D, Puri B, Singh I, Dhaliwal R. The overweight: obesity and plasma lipids in adults with intellectual disability and mental illness. J Intell Disabil Res. 2012;56:895–901.CrossRef
17.
Fodstad JC, Bamburg JW, Matson JL, Mahan S, Hess JA, Neal D, et al. Tardive Dyskinesia and intellectual disability: an examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use. Res Dev Disabil. 2010;31:750–9.CrossRefPubMed
18.
Frighi V, Morovat A, Stephenson MT, White SJ, Hammond CV, Goodwin GM. Vitamin D deficiency in patients with intellectual disabilities: prevalence, risk factors and management strategies. Brit J Psychiat. 2014;205:458–64.CrossRefPubMed
19.
Matson JL, Mahan S. Antipsychotic drug side effects for persons with intellectual disability. Res Dev Disab. 2010;31:1570–6.CrossRef
20.
Edelsohn GA, Schuster JM, Castelnovo K, Terhorst L, Parthasarathy M. Psychotropic prescribing for persons with intellectual disabilities and other psychiatric disorders. Psychiat Serv. 2014;65:201–7.CrossRef
21.
Hsia Y, Wong AY, Murphy DG, Simonoff E, Buitelaar JK, Wong IC. Psychopharmacological prescriptions for people with autism spectrum disorder: a multinational study. Psychopharmacology. 2014;231:999–1009.CrossRefPubMed
22.
Wong A, Hsia Y, Chan EW, Murphy DG, Simonoff E, Buitelaar JK, et al. The variation of psychopharmacological prescription rates for people with autism spectrum disorder in 30 countries. Autism Res. 2014;231:543–54.CrossRef
23.
Murray ML, Hsia Y, Glaser K, Simonoff E, Murphy DG, Asherson PJ, et al. Pharmacological treatments prescribed to people with autism spectrum disorder in primary health care. Psychopharmacology. 2014;231:1011–21.CrossRefPubMed
24.
Buszewicz M, Welch C, Horsfall L, Nazareth I, Osborn D, Hassiotis A, et al. Assessment of an incentivised scheme to provide annual health checks in primary care for adults with intellectual disability: a longitudinal cohort study. Lancet Psychiat. 2014;1:522–30.CrossRef
25.
National Institute for Health and Clinical Excellence (NICE). The Guidelines Manual. London: NICE; November 2012. www.​nice.​org.​uk. Accessed 8 Nov 2013.
26.
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. www.​cochrane-handbook.​org. Accessed 8 Nov 2013.
27.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. 10th ed. Geneva: World Health Organization; 1992.
28.
La Malfa G, Lassi S, Bertelli M, Salvini R, Placidi G. Autism and intellectual disability: a study of prevalence on a sample of the Italian population. J Intellectual Disability Res. 2004;48(3):262–7.CrossRef
29.
National Institute for Health and Clinical Excellence (NICE). Autism: the management and support of children and young people on the autism spectrum. NICE Clinical Guideline 170. London: NICE; 2013.
30.
National Institute for Health and Care Excellence (NICE): Clinical Guideline [NG11]. Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. British Psychological Society/Royal College of Psychiatrists; 2015. www.​nice.​org.​uk. Accessed 7th June 2015.
31.
32.
Cohen J. Statistical power analysis for the behavioral sciences. Hilllsdale, NJ: Erlbaum; 2013.
33.
Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer I. 1959;22:719–48.
34.
Furuya-Kanamori L, Doi SAR. The outcome with higher baseline risk should be selected for relative risk in clinical studies: a proposal for change to practice. J Clin Epidemiol. 2014;67:364–7.CrossRefPubMed
35.
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–6.CrossRefPubMed
36.
Akhondzadeh S, Tajdar H, Mohammadi MR, Mohammadi M, Nouroozinejad GH, Shabstari OL, et al. A double-blind placebo controlled trial of piracetam added to risperidone in patients with autistic disorder. Child Psychiat Hum Dev. 2008;39:237–45.CrossRef
37.
Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Hagerman R, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiat. 2002;159:1337–46.CrossRefPubMed
38.
Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiat. 2012;71:956–61.CrossRefPubMedPubMedCentral
39.
Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adol Psychop. 2005;15:682–92.CrossRef
40.
Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacol. 2010;35:990–8.CrossRef
41.
Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, et al. Risperidone dosing in children and adolescents with autistic disorder: A double-blind, placebo-controlled study. J Autism Dev Disord. 2013;43:1773–83.CrossRefPubMed
42.
Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adol Psychiat. 2001;40:887–94.CrossRef
43.
Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adol Psychiat. 2009;48:1110–9.CrossRef
44.
Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124:1533–40.CrossRefPubMed
45.
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. New Engl J Med. 2002;347:314–21.CrossRefPubMed
46.
Ghanizadeh A, Sahraeizadeh A, Berk M. A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiat Hum Dev. 2013;1–8.
47.
Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh SA, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress Neuropsychopharmacol Biol Psychiat. 2010;34:1269–72.CrossRef
48.
Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114:e634–41.CrossRefPubMed
49.
Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J American Acad Child Adol Psychiat. 2002;41:1026–36.CrossRef
50.
Aman MG, Tassé MJ, Rojahn J, Hammer D. The Nisonger CBRF: a child behavior rating form for children with developmental disabilities. Res Dev Disabil. 1996;17:41–57.CrossRefPubMed
51.
Aman MG, Singh NN, Stewart AW, Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Def. 1985;89:485–91.
52.
Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiat. 2007;4:28–37.
53.
Coccaro EF, Harvey PD, Kupsaw-Lawrence E, Herbert JL, Bernstein D. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiat Clin N. 1991;3:S44–51.
54.
55.
Kleinberg DL, Davis JM, De Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19:57–61.CrossRefPubMed
56.
Naidoo U, Goff D, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendo. 2003;28:97–108.CrossRef
57.
Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psych. 2015;72:867–74.CrossRef
58.
59.
60.
Farmer CA, Aman MG. Pharmacological intervention for disruptive behaviors in intellectual and developmental disabilities: the glass is half full. In: Hastings RP, Rojahn J, editors. International review of research in developmental disabilities. London: Elsevier; 2013. p. 281–325.
61.
Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. New Engl J Med. 2008;358:1427–9.CrossRefPubMed
Metadata
Title
Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis
Authors
Cheryl McQuire
Angela Hassiotis
Bronwyn Harrison
Stephen Pilling
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2015
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-015-0688-2

Other articles of this Issue 1/2015

BMC Psychiatry 1/2015 Go to the issue

Study protocol

Study protocol: cross-national comparative case study of recovery-focused mental health care planning and coordination (COCAPP)

Research article

Motivation to change and perceptions of the admission process with respect to outcome in adolescent anorexia nervosa

Research article

Can mental health interventions change social networks? A systematic review

Study protocol

Wellbeing and resilience: mechanisms of transmission of health and risk in parents with complex mental health problems and their offspring—The WARM Study

Research article

Antipsychotic drug exposure and risk of pulmonary embolism: a population-based, nested case–control study

Research article

Experiences of adolescents and young adults with ADHD in Hong Kong: treatment services and clinical management